Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02005315
Title A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors OncoMed Pharmaceuticals, Inc.
Indications

pancreatic adenocarcinoma

Therapies

Gemcitabine + Nab-paclitaxel + Vantictumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.